AnaPath Research is a global CRO based near Barcelona, providing research and development services for various industries including pharmaceuticals, biotechnology, agriculture, and chemistry. This article investigates and summarizes the company's features and information on its disease models.
At AnaPath Research, to confirm the safety of new drug candidates,Supports a wide range of in vivo (in the body) testsWe can handle general repeated-dose toxicity studies, reproductive and developmental toxicity studies, and safety pharmacology studies evaluating the central nervous system and cardiovascular system.A specialized team with extensive experience conducts comprehensive risk assessments from the initial stage.We support the development of pharmaceuticals by doing this.
In addition to low-molecular-weight compounds, recombinant proteins, monoclonal antibodies, gene therapy drugs, and otherProvision of analytical services for biologics (biopharmaceuticals)We are engaged in a wide range of specialized bioanalytical services to meet regulatory requirements. This includes method development and validation for pharmacokinetics (PK) and toxicokinetics (TK), as well as measurement of anti-drug antibodies (ADAs) and quantification of biomarkers.
The company is the standard for conducting drug safety tests.GLP (Good Laboratory Practice) certified facilityand we provide reliable test data. Furthermore,Accreditation from AAALAC, an international animal welfare organizationWe also have strict auditing systems in place, implemented by a quality assurance team with many years of experience, ensuring ethical and appropriate handling.
AnaPath Research is a CRO that conducts studies directly at its own facilities. For safety assessments and toxicity testing, we appropriately select and utilize a diverse range of animal models, from rodents (rats and mice) to non-rodents (dogs, minipigs, and non-human primates), depending on the characteristics of each compound.
While AnaPath Research's official website does not feature specific non-clinical study examples, the company conducts safety evaluation studies for a wide range of compounds.
Due to confidentiality of individual sponsor names and specific development compounds in safety assessment studies, detailed study examples are not disclosed. However, from the era of its predecessor testing facility, the company has decades of experience in conducting GLP-compliant studies across a wide range of fields, including pharmaceuticals, medical devices, and agricultural chemicals, and has a proven track record of contributing to regulatory applications in various countries.
| Address | Barcelona, Spain |
|---|---|
| Tel | +34 93 719 03 61 |
| Website | https://www.anapathresearch.com/ |
In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.
SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.
SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.
Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.
With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.
Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.
Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.
Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.
Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.
Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.
PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.
Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.
Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.